drugset
Drugs / DNA-HIV-PT123
last change Dec 2024 re-read 2 minutes ago

DNA-HIV-PT123

Vaccine

Developed for
HIV infectious disease
Investigated by
EuroVacc Foundation · National Institute of Allergy and Infectious Diseases (NIAID) · Centre Hospitalier Universitaire Vaudois · International AIDS Vaccine Initiative · MRC/UVRI and LSHTM Uganda Research Unit · ANRS, Emerging Infectious Diseases
+22 more · HIV Vaccine Trials Network · IPPOX Foundation · Imperial College London · Medical Research Council · CONRAD · Chelsea and Westminster Hospital, UK · European Commission · Gilead Sciences · Global Solutions for Infectious Diseases · Global Solutions for Infectious Diseases (GSID) · Henri Mondor University Hospital · Instituto Nacional de Saúde, Mozambique · Karolinska Institutet · King's College London · Ludwig-Maximilians - University of Munich · Medical Research Council, South Africa · Muhimbili University of Health and Allied Sciences · National Institute for Medical Research, Tanzania · Recherche Clinique Paris Descartes Necker Cochin Sainte Anne · Swiss Government · University College London Hospitals · University College, London

Trials 10 · a red edge is where a trial was stopped

today NCT04844775 · Ph 1 NCT04842682 · Ph 1 NCT04066881 · Ph 2 NCT03391375 · Ph 1 NCT01927835 · Ph 1 NCT02376582 · Ph 1 NCT02207920 · Ph 1 NCT01964937 · Ph 1 NCT01783977 · Ph 1 NCT01799954 · Ph 1
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 19 trials
Phase 1 NCT04844775 Aug 2022 → Sep 2024 — ANRS, Emerging Infectious Diseases Completed No outcome recorded
Phase 1 NCT04842682 Mar 2021 → Nov 2024 — ANRS, Emerging Infectious Diseases Completed No outcome recorded
Phase 1 NCT03391375 Mar 2017 → Jan 2018 HIV infectious disease EuroVacc Foundation Completed No outcome recorded
Phase 1 NCT02376582 Sep 2014 → Jan 2016 HIV infectious disease EuroVacc Foundation Completed No outcome recorded
Phase 1 NCT02207920 Jul 2014 → Dec 2015 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01783977 Apr 2013 → Sep 2014 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 1 NCT01799954 Aug 2012 → Dec 2014 HIV infectious disease HIV Vaccine Trials Network Completed No outcome recorded
Phase 1 NCT01964937 ? → Apr 2014 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded
Phase 1 NCT01927835 ? → Jan 2017 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Withdrawn No outcome recorded
Phase 21 trial
Phase 2 NCT04066881 Dec 2020 → Dec 2024 HIV infectious disease MRC/UVRI and LSHTM Uganda Research Unit Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02997969 Comparator Jun 2016 → Jul 2018 HIV infectious disease National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as DNA-HIV-PT123 “The proposed vaccine trial will generate safety, tolerability and immunogenicity data of a vaccination regimen with simultaneous administration of a candidate HIV DNA vaccine...” NCT02376582 ↗
10

“combined with DNA-HIV-PT123 HIV-1 at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24” NCT04842682 ↗

NCT02207920 ↗

NCT04066881 ↗

NCT01799954 ↗

NCT03391375 ↗

NCT01783977 ↗

NCT01927835 ↗

NCT02997969 ↗

NCT04844775 ↗

NCT01964937 ↗
Modality Vaccine “DNA HIV vaccine” NCT01783977 ↗
Route Intramuscular “administered as 1 mL IM in participant's deltoid” NCT01783977 ↗